Prevalence of drug resistance mutations over time in naïve HIV+ subjects living in Spain.
authors
Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Leal M, Clotet B, Soriano V.
Presented at the 6th National Conference on HIV and Opportunistic Infections, Chicago, Feb 1-4, 1999.
publication
6th National Conference on HIV and Opportunistic Infections. 31 Jan-4 Feb 1999, Chicago, IL. Abstract 125.
ABSTRACT
Mutant viruses can be transmitted, leading to primary drug resistance in newly infected persons. To determine the prevalence of primary drug resistance and to recognise any trend over time, we examined plasma samples collected from naïve subjects in 1993 (n=75) and 1997 (n=75), as well as in a group of patients who had seroconversion during the protease inhibitor's era (after January 1997). As hypothesis, in the PI era, the probability of HIV transmission should be lower since many subjects are treated with potent combinations and harbour very low viral load. However, if transmission occurs, the probability of new infections with resistant viruses should be higher.
The LiPA assay was used for recognising the mutations associated to RT nucleoside inhibitors. Moreover, a point mutation nested PCR was used for examining the codon 151 mutation associated with multiple drug resistance.
naïve 1993
naïve 1997
Seroconvertors in the PI era
Study population
75
75
25
Persons with mutant viruses
10 (13.3%)
9 (12%)
3 (12%)
RT mutations:
41/70/215(ZDV)
74 (ddI)
184 (3TC)
1/7/0
1
1
3/5/1
0
0
1/0/0
0
2
Conclusions: There is no evidence for an increase in the prevalence of primary drug-resistant genotypes in Spain over the last 5 years, remaining around 12%. Mutations associated to ZDV are the most frequently seen, although 3TC mutants were the most common among recent seroconvertors. Up to now, no mutants at codon 151 have been recorded among naïve subjects in Spain.
